Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2023
Filter by date:
Showing 1262 press releases before 2023
-
Vaxzevria significantly boosted antibody levels against Omicron
-
Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in studies from Oxford and Washington Universities
-
Ultomiris regulatory submission accepted under FDA Priority Review in the US for adults with generalised myasthenia gravis
-
Saphnelo recommended for approval in the EU by CHMP for the treatment of patients with systemic lupus erythematosus
-
Tezspire (tezepelumab) approved in the US for severe asthma
-
Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in independent FDA study
-
Calquence reduced the risk of disease progression or death by 71% vs. standard of care combinations at three years in the ASCEND Phase III trial
-
Enhertu additional analyses further reinforce ground-breaking efficacy in patients with HER2-positive metastatic breast cancer
-
Evusheld (formerly AZD7442) long-acting antibody combination authorised for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19
-
AstraZeneca and Ionis sign deal to develop and commercialise eplontersen
Latest articles and press releases
All of our latest press releases and articles are available to explore
Use a maximum of two downloads here
